

APPENDIX 5

FORMS RELATING TO LISTING

FORM F

THE GROWTH ENTERPRISE MARKET (GEM)

COMPANY INFORMATION SHEET

Case Number:

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this information sheet, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this information sheet.

Company name:	Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Stock code (ordinary shares):	08058

This information sheet contains certain particulars concerning the above company (the "Company") which is listed on the Growth Enterprise Market ("GEM") of the Stock Exchange of Hong Kong Limited (the "Exchange"). These particulars are provided for the purpose of giving information to the public with regard to the Company in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules"). They will be displayed at the GEM website on the Internet. This information sheet does not purport to be a complete summary of information relevant to the Company and/or its securities.

The information in this sheet was updated as of <u>1 July 2016</u>

A. General

Place of incorporation:	People's Republic of China
Date of initial listing on GEM:	9 December 2005
Name of Sponsor(s):	Kingsway Capital Limited
Names of directors: (please distinguish the status of the director - Executive, Non-Executive or Independent Non-Executive)	Executive Directors Mr. Liu Baoqi Ms. Li Minghua Mr. Han Fengsheng Mr. Chen Yu Mr. Liu Zhenteng
	Non-executive Directors Mr. Liu Zhenhai Independent Non-executive Directors
	Mr. Foo Tin Chung, Victor Mr. Fu Hongzheng Prof. Du Guanhua

Ms. Huang Huiwen

Name(s) of substantial shareholder(s): (as such term is defined in rule 1.01 of the GEM Listing Rules) and their respective interests in the ordinary shares and other securities of the Company	Name Shandong Luoxin Holdings Co., Ltd.	No. of ordinary shares held 325,639,949	Approximate percentage of issued share capital 53.42%
Name(s) of company(ies) listed on GEM or the Main Board of the Stock Exchange within the same group as the Company:	N/A		
Financial year end date:	31 December		
Registered address:	Luoqi Road, Linyi High and N Development Zone, Shandong Province, PRC	New Technology Ind	
Head office and principal place of business:	Unit 10, 11/F, Tower B, Sout 11 Yip Hing Street, Wong Ch Hong Kong	nuk Hang,	
Web-site address (if applicable):	www.luoxin.cn		
Share registrar:	Computershare Hong Kong I Rooms 1712-16, 17 th Floor, Hopewell Centre, 183 Queer Hong Kong		mited
Auditors:	HLB Hodgson Impey Cheng 31/F, Gloucester Tower, The Landmark, 11 Pedder St., Central, Hong Kong		

B. Business activities

Manufacturing and selling of pharmaceutical products, wholesale of biochemical and Chinese medicine, development, technology transfer, technology consultancy and technology services of biological products, pharmaceutical products and medical equipments, and investment holdings.

C. Ordinary shares

Number of ordinary shares in issue:	609,600,000
Par value of ordinary shares in issue:	RMB0.1 per share
Board lot size (in number of shares):	2,000 ordinary shares
Name of other stock exchange(s) on which ordinary shares are also listed:	N/A

D. Warrants

Stock code:

Board lot size:	N/A
Expiry date:	N/A
Exercise price:	N/A
Conversion ratio: (Not applicable if the warrant is denominated in dollar value of conversion right)	N/A
No. of warrants outstanding:	N/A
No. of shares falling to be issued upon the exercise of outstanding warrants:	N/A

E. Other securities

Details of any other securities in issue.

(i.e. other than the ordinary shares described in C above and warrants described in D above but including options granted to executives and/or employees).

(Please include details of stock code if listed on GEM or the Main Board or the name of any other stock exchange(s) on which such securities are listed).

If there are any debt securities in issue that are guaranteed, please indicate name of guarantor.

N/A

Responsibility statement

The directors of the Company (the "Directors") as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this information sheet ("the Information") and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information is accurate and complete in all material respects and not misleading or deceptive and that there are no other matters the omission of which would make any Information inaccurate or misleading.

The Directors also collectively and individually accept full responsibility for submitting a revised information sheet, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.

The Directors acknowledge that the Stock Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information.

Signed:

Liu Baogi	Li Minghua
Han Fengsheng	Chen Yu
Liu Zhenteng	Liu Zhenhai
Foo Tin Chung, Victor	Fu Hongzheng
Prof. Du Guanhua	Huang Huiwen

NOTES

- (1) This information sheet must be signed by or pursuant to a power of attorney for and on behalf of each of the Directors of the Company.
- (2) Pursuant to rule 17.52 of the GEM Listing Rules, the Company must submit to the Exchange (in the electronic format specified by the Exchange from time to time) for publication on the GEM website a revised information sheet, together with a hard copy duly signed by or on behalf of each of the Directors, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.
- (3) Please send a copy of this form by facsimile transaction to Hong Kong Securities Clearing Company Limited (on 2815-9353) or such other number as may be prescribed from time to time) at the same time as the original is submitted to the Exchange.